Stockreport

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF Data presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repar [Read more]